62078-78-8

Usage

Uses

Used in Organic Synthesis:
1-Naphthalenamine,6-fluoro-(9CI) is used as a building block for the preparation of various functionalized aromatic compounds. Its presence in organic synthesis allows for the creation of a wide range of chemical products due to its unique structure and reactivity.
Used in Research:
1-Naphthalenamine,6-fluoro-(9CI) is utilized in research for exploring new chemical reactions and applications. The presence of the fluorine atom in 1-Naphthalenamine,6-fluoro-(9CI) may impart unique properties and reactivity, making it a valuable tool for scientific exploration and advancement in the field of chemistry.
Used in Pharmaceutical Development:
1-Naphthalenamine,6-fluoro-(9CI) may have applications in the development of pharmaceuticals. Its unique structure and potential reactivity could contribute to the design and synthesis of new drug candidates for various therapeutic areas.
Used in Agrochemical Development:
1-Naphthalenamine,6-fluoro-(9CI) may also be employed in the development of agrochemicals. Its properties could be harnessed to create new products for agricultural applications, potentially improving crop protection and yield.
Used in Materials Science:
1-Naphthalenamine,6-fluoro-(9CI) could be utilized in materials science for the development of new materials with specific properties. The incorporation of a fluorine atom might provide 1-Naphthalenamine,6-fluoro-(9CI) with unique characteristics that could be beneficial in material development processes.

Upstream product

• 575-08-6 6-fluoro-1-naphthalenecarboxylic acid 
• 59080-29-4 (Z)-6-fluoro-3,4-dihydronaphthalen-1(2H)-one oxime 

Downstream Products

• 904923-95-1 1-chloro-6-fluoronaphthalene 

Relevant academic research and scientific papers

CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Disclosed are a condensed ring derivative, and a preparation method, an intermediate, a pharmaceutical composition and a use thereof. The condensed ring derivative of the present invention has a significant inhibitive effect on URAT1, which can effectively alleviate or treat hyperuricemia and other related diseases.

DIHYDROIMIDAZOTHIAZOLE DERIVATIVES

Compounds of formula (I): or pharmaceutically acceptable salts thereof, exhibit 5-HT1A agonism in addition to noradrenaline reuptake inhibition and optionally also 5-HT reuptake inhibition are useful for the treatment of obesity.

METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY

A method for treating glaucoma and ischemic retinopathy in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of the formula or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and A

Method of treating psychiatric conditions

A method for treating a psychiatic condition or disorder selected from anxiety disorders such as panic disorder, posttraumatic stress disorder and phobias, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder and mood disorders associated with psychotic disorders such as acute mania or depression associated with bipolar disorder, schizophrenia, behavioral manifestations of mental retardation, conduct disorder or autistic disorder, dementias such as dementias of the Alzheimer's type, and dyskinesias such as drug induced and neurodegeneration based dyskinesias in a mammal, including a human, comprising administering to said mammal a pharmaceutically effective amount of a compound of the formula or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.

Method of treating tourette's syndrome and obsessive compulsive disorder

A method for treating Tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of the formula STR1 or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.

Method of treating tourette's syndrome

The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating Tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal, including a human wherein n, X, Y and Ar are as defined herein.

Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds

Arylpiperazinyl-alkylenephenyl-p-heterocyclic compounds, and the pharmaceutically acceptable acid addition salts thereof are neuroleptic agents. They are useful in the treatment of psychotic disorders.

Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity

Arylpiperazinyl-ethyl(or butyl)-heterocyclic compounds and their pharmaceutically acceptable acid addition salts are neuroleptic agents. They are useful in the treatment of psychotic disorders.

Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds

An arylpiperazinyl-alkylenephenyl-p-heterocyclic compound, useful in the treatment of psychotic disorders, of the formula- or a pharmaceutically-acceptable acid-addition salt thereof,wherein:-, Ar is phenyl, 3-trifluoromethylphenyl, 3-cyanopyridyl, naphth

Piperazinyl-heterocyclic compounds

Arylpiperazinyl-ethyl(or butyl)-heterocyclic compounds and their pharmaceutically acceptable acid addition salts are neuroleptic agents. They are useful in the treatment of psychotic disorders.